Here are five things to know:
1. The policy is effective June 15, 2016.
2. Geisinger Health Plan covers more than 500,000 people in Delaware, Maine, New Jersey, Pennsylvania and West Virginia.
3. The policy states other fusion products for sacroiliac joint fusion are “considered experimental/investigational or unproven and therefore not covered.”
4. The iFuse Implant System’s triangular shape is designed to provide 31 times the rotational resistance of a screw.
5. The product’s FDA clearance supports clinical study results for the system proving enhanced pain, patient function and quality of life.
More articles on spine:
Spine surgeon Dr. Michael Janssen helps powerboat racers make a splash back in the water — 4 highlights
NY Top Doc names Mount Sinai Health System’s Dr. Saad Chaudhary to esteemed list: 5 points
Irregular cerebrospinal fluid flow connected to idiopathic scoliosis — 6 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
